Overview

A Phase 2 Evaluation of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members and Veterans With PTSD

Status:
Not yet recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Subjects are randomized among the multiple cohorts in the study and the resulting randomization enables sharing/pooling of control subjects, where all interventions may be compared to a common control (placebo). This master protocol describes the default procedures and analyses for all cohorts; treatment-specific procedures will be described in the platform cohort appendices and individual cohorts may have additional eligibility requirements or safety and efficacy procedures.

Phase:

Phase 2

Details

Lead Sponsor:

U.S. Army Medical Research and Development Command

Collaborator:

PPD

Treatments:

Fluoxetine
Vilazodone Hydrochloride